

14. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P, and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. *N Engl J Med* 334: 939–945, 1996
15. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS, and the ACE Inhibition in Progressive Renal Disease Study Group: Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data. *Ann Intern Med* 135: 73–87, 2001
16. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 349: 1857–1863, 1997
17. Mallamaci F, Ruggenenti P, Perna A, Leonardi D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C: ACE inhibition is renoprotective among obese patients with proteinuria. *J Am Soc Nephrol* 22: 1122–1128, 2011
18. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. *Ann Intern Med* 144: 21–28, 2006
19. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA: Angiotensin II increases adipose angiotensinogen expression. *Am J Physiol Endocrinol Metab* 292: E1280–E1287, 2007
20. Tuck ML, Sowers J, Domfeld L, Kledzik G, Maxwell M: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. *N Engl J Med* 304: 930–933, 1981
21. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. *Hypertension* 45: 356–362, 2005
22. Stier CT, Mahboubi K, DiPippo VA, Levine S, Chander PN: The anti-proteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. *J Pharmacol Exp Ther* 260: 1410–1415, 1992
23. Bombardieri AS, Kshirsagar AV, Whaley-Connell AT, Chen SC, Li S, Klemmer PJ, McCullough PA, Bakris GL: Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis* 55(3 Suppl 2): S4–S14, 2010
24. Navaneethan SD, Schold JD, Srinivas TR: Metabolic syndrome and mild to moderate chronic kidney disease among minorities. *Semin Nephrol* 30: 51–58, 2010
25. Elsayed EF, Samak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, Levey AS, Weiner DE: Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. *Am J Kidney Dis* 52: 29–38, 2008

See related article, “ACE Inhibition Is Renoprotective among Obese Patients With Proteinuria,” on pages 1122–1128.

## Trials and Tribulations of New Agents, Novel Biomarkers, and Retarding Renal Progression

Adeera Levin and Monica C. Beaulieu

Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada

*J Am Soc Nephrol* 22: 992–993, 2011.  
doi: 10.1681/ASN.2011040402

Inflammation and fibrosis are important processes that mediate progression of kidney disease. Agents that interfere with these processes need to be studied in sufficient detail in humans so we may begin to offer some hope to patients and populations with kidney disease. Diabetic nephropathy remains the most common cause of end-stage renal disease (ESRD) worldwide, and as there are an increasing number of people developing diabetes, in both developed and developing countries, the need for treatments that delay progression or attenuate the course of the disease is ever pressing.

Sharma *et al.*, in the current issues of *JASN*, describe the results of a small, randomized control trial with an oral anti-fibrotic, anti-inflammatory agent, pirfenidone.<sup>1</sup> This agent has shown promise in animal studies of diabetes or lung fibrosis and small human open-label studies in patients with FSGS and with pulmonary fibrosis.<sup>2–5</sup> This study enrolled 77 patients who were randomly assigned to placebo or two different doses of the pirfenidone. All patients received baseline medication for renin-angiotensin system blockade and the majority were type 2 diabetics. Overall, the study reports only the results of those who actually completed the study ( $n = 52$ ) over a period of one year and notes the relatively high number of dropouts, particularly in the high-dose pirfenidone group. The authors describe statistically different changes in eGFR between low-dose pirfenidone and placebo, and a nonsignificant result when the placebo group was compared with those who received pirfenidone at any dose. The authors acknowledge the shortcomings of the trial but are encouraged by the results and then call for larger studies.

Close review of this paper and accompanying literature, however, reveals that there are a number of unanswered questions that need to be carefully considered before embarking on these larger trials. First, those on the higher dose of pirfenidone had a greater drop in their eGFR in the first 3 mo of the study than either placebo or low dose groups. This is not explained and is counterintuitive. The higher-dose group had substantial side effects, mostly gastrointestinal, so that tolerability of the drug is an important issue for future consideration. There are no changes in the inflammatory or pro-fibrotic serum biomarkers over time, despite their correlation with eGFR at baseline, nor are there any changes in these serum biomarkers as a function of treatment, despite the purported mechanism of action of the agent being the inhibition of TGF $\beta$  production and subsequent matrix accumulation. Furthermore, even in patients with response to the drug, there are no changes in urine levels of the albumin-creatinine ratio or TGF $\beta$  over the study duration. The end point in this study is a surrogate: eGFR using standardized creatinine measurements and the four variable MDRD equation

Published online ahead of print. Publication date available at www.jasn.org.

**Correspondence:** Dr. Adeera Levin, Department of Nephrology, Street Paul Hospital, 1081 Burrard Street Room 6010A Providence Wing, Vancouver, British Columbia V6Z 1W8 Canada. Phone: 604-682-2344, x62510; Fax: 604-806-8120; Email: alevin@providencehealth.bc.ca

Copyright © 2011 by the American Society of Nephrology

but no direct measurements of GFR. Interestingly, previous studies using this agent that have been conducted over the last decade have not yet led to any larger scale studies.

These specific issues and inconsistencies serve to caution enthusiasm and give reason to ponder the best study design and framework in which to study such agents. Given the increasing interest in biologic pathways and agents that interfere with them, it is important to set up a framework in which new agents that modulate biologic pathways should be evaluated.

In particular, given the heterogeneity of the human disease conditions, it would be prudent to phenotype individuals and randomize them according to more precise descriptors rather than presence or absence of diabetes. Many have acknowledged the biologic variability of kidney disease itself,<sup>6</sup> so that it behoves us to take that into account in the design of clinical studies. More precise biomarker profiles could have been determined at baseline,<sup>7</sup> and stratification by level of pro-fibrotic or pro-inflammatory markers could have been conducted. Second, in studies of renal progression, there is a need to correlate biomarkers with tissue damage, and the use of kidney biopsies should be encouraged,<sup>8</sup> both at baseline and serially if possible. Third, given the importance of the question regarding progression, estimates of kidney function are not acceptable in small trials. Simple, but robust, direct measurements such as iohexal or radionucleotide measurements should be undertaken. And last, evaluation of these new therapies should be undertaken over a minimum duration of 18 to 24 mo.

Imagine that the current study had serial biopsies, direct measurements of GFR instead of estimates, and that patients were all either type 1 or type 2 diabetics, with no differential in baseline kidney function or albumin excretion. If the same results were described, but with biopsy confirmed evidence of regression or lack of progression with respect to tissue fibrosis, staining for TGF $\beta$  or other biomarkers, we may be less concerned about some of the inconsistencies noted in the presented results. Similarly, if the biopsy results were not supportive of any real change in fibrosis or matrix expansion, then the encouraging results of eGFR changes would have been tempered, especially since no changes in any of the inflammatory biomarkers studied were noted.

Clinical studies of human kidney disease with biologic agents that address key pathologic processes are needed. The excitement of preliminary studies with specific agents needs to be tempered with caution, given the absence of consistent and robust data. Furthermore, the probability of any single agent being effective in the context of the complexity of fibrosis<sup>9</sup> and inflammatory pathways<sup>10</sup> is suspect, and needs to be considered in the design of the studies. The addition of new agents to current standard of care, as was done in this study, is important. The conduct of clinical trials is difficult, fraught with numerous regulatory and ethical hurdles. The study by Sharma *et al.* is a reasonable start,<sup>1</sup> but carefully performed physiologic studies are required before embarking on larger-scale clinical trials.

We would propose a consistent framework of study for these new agents that includes harder end points (as in measured GFR and biopsies where feasible), better phenotyping of individuals enrolled in studies, and longer duration of follow-up. The systematic evaluation of a series of different agents could then be conducted using this framework, which would help with comparisons between different molecules and extend our knowledge of pathobiology of disease. In so doing, we would establish a standard that would move the scientific community forward at a significant pace. Until that time, the results of this and other similar trials must be looked upon with cautious optimism but tempered enthusiasm.

## DISCLOSURES

None.

## REFERENCES

- Sharma K, Joachim H, Ix JH, Mathew AV, Cho M, Pflueger A, R., DS, Francos B, Sharma S, Falkner B, McGowan TA, Michael Donohue M, Rao SR, Xu R, Fervenza FC, Kopp, JB: Pirfenidone in diabetic nephropathy. *J Am Soc Nephrol* 22: 1144–1151, 2011
- Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol* 2: 906–913, 2007
- Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. *Mol Genet Metab* 76: 234–242, 2002
- Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN: Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. *J Lab Clin Med* 125: 779–785, 1995
- Rao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, Shaw MA, Sharma K: Pirfenidone is renoprotective in diabetic kidney disease. *J Am Soc Nephrol* 20: 1765–1775, 2009
- Siew ED, Ware LB, Ikizler, TA: Biological markers of acute kidney injury. *J Am Soc Nephrol* 22: 810–820, 2011
- Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, Bertram CC, Page GP, Rovin BH, Warram JH, Krolewski AS, Klein JB: Urinary peptideome may predict renal function decline in type 1 diabetes and microalbuminuria. *J Am Soc Nephrol* 20: 2065–2074, 2009
- Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noel LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA: Pathologic classification of diabetic nephropathy. *J Am Soc Nephrol* 21: 556–563, 2010
- Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. *J Am Soc Nephrol* 21: 1819–1834, 2010
- Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA: The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. *J Am Soc Nephrol* 21: 1732–1744, 2010

See related article, "Pirfenidone for Diabetic Nephropathy," on pages 1144–1151.